Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Mar 31, 2018
Dec 31, 2017
Sep 30, 2017
Jun 30, 2017
Total Revenue
373,447
358,305
334,148
317,448
Cost of Revenue
82,333
75,995
59,480
56,305
Gross Profit
291,114
282,310
274,668
261,143
Operating Expenses
Research Development
183,948
168,608
154,103
143,039
Selling General and Administrative
138,336
160,280
130,532
143,505
Non Recurring
--
--
--
--
Others
13,202
20,375
3,760
13,411
Total Operating Expenses
335,486
349,263
288,395
299,955
Operating Income or Loss
(44,372)
(66,953)
(13,727)
(38,812)
Income from Continuing Operations
Total Other Income/Expenses Net
(104)
128,393
14
(7,523)
Earnings Before Interest And Taxes
(39,242)
62,537
(9,737)
(43,352)
Interest Expense
11,562
7,939
10,884
2,194
Income Before Tax
(50,804)
54,598
(20,621)
(45,546)
Income Tax Expense
(6,655)
105,990
(8,094)
(8,713)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(44,149)
(51,392)
(12,527)
(36,833)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(44,149)
(51,392)
(12,527)
(36,833)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(44,149)
(51,392)
(12,527)
(36,833)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information